SCHEMBL21708697

SCHEMBL21708697

CCCC(F)OC(=O)CC(CN)c1ccccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C9 P11712 3/20 0.34
TSHR P16473 3/20 0.34
CYP2C19 P33261 3/20 0.34
MAPK1 P28482 2/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX2 P34913 2/20 0.33
PPARG P37231 2/20 0.33
SLC6A4 P31645 1/20 0.33
CACNA2D1 P54289 1/20 0.33
CACNA1B Q00975 1/20 0.33
CACNB1 Q02641 1/20 0.33
CACNA1C Q13936 1/20 0.33
KCNK3 O14649 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708531 0.90 PTGFR (0.35) CNR2KDM4EKMT2ACYP1A2CYP3A4
SCHEMBL21708766 0.84 GABBR2 (0.33) MAPK1SLC6A4POLB
SCHEMBL21708713 0.84 KCNK3 (0.37) KCNK3KCNK9POLBPTGFR
SCHEMBL21708646 0.83 NISCH (0.37) KDM4EKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL21708643 0.83 POLB (0.45) KMT2ATSHRHPGDPPARGPOLB
Hydrochloric Acid SCHEMBL21708730 0.81 CTDSP1 (0.36) KDM4EKMT2ATSHRPPARGPOLB
SCHEMBL13703411 0.81 CNR2 (0.43) CNR2KDM4EKMT2ACYP1A2CYP3A4
SCHEMBL21708746 0.81 CNR2 (0.34) CNR2KDM4EKMT2ACYP1A2CYP3A4
SCHEMBL21656116 0.79 POLB (0.40) CNR2KDM4EKMT2AMAPK1HPGD
SCHEMBL21632052 0.76 GABBR2 (0.56) CNR2KMT2ACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609869-A1 SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2020-02-19 EP disclosed